Johnson & Johnson (JNJ) just made life a bit easier for lung cancer patients. The FDA approved a new monthly dosing schedule on Tuesday for the company's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) when given alongside oral Lazcluze (lazertinib) as first-line treatment for advanced non-small cell lung cancer with EGFR mutations.
Here's why this matters: The monthly dosing delivers the same results as the previously approved bi-weekly subcutaneous schedule, but patients spend less time dealing with treatment logistics. Instead of showing up every two weeks, they can transition to once-monthly visits as early as Week 5 of their therapy.
This approval extends recent momentum for Rybrevant Faspro. Back in December 2025, the FDA cleared it as the first subcutaneously administered therapy for EGFR-mutated NSCLC. That was already a significant upgrade because it slashed administration time from hours down to minutes and delivered a fivefold reduction in administration-related reactions compared to traditional intravenous delivery.
The new monthly schedule is now approved across all indications where Rybrevant is already cleared, giving doctors and patients more flexibility in treatment planning.
"A monthly dosing schedule offers patients convenience without sacrificing efficacy," said Danny Nguyen, principal investigator for the PALOMA-3 and MARIPOSA studies.
The evidence backing this approval comes from PALOMA-2 data presented at the 2025 World Conference on Lung Cancer. The study showed that monthly Rybrevant Faspro dosing combined with Lazcluze produced a high objective response rate in previously untreated patients with EGFR-mutated advanced NSCLC. Administration-related reactions dropped significantly compared to historical IV delivery, while remaining consistent with the bi-weekly subcutaneous approach.
For context, EGFR-mutated non-small cell lung cancer represents a specific subset of lung cancer cases where certain genetic mutations drive tumor growth. Targeted therapies like Rybrevant work by attacking these specific mutations rather than using traditional chemotherapy's broader approach.
Stock Performance: Johnson & Johnson shares were down 0.35% at $242.59 at the time of publication on Tuesday, trading close to the stock's 52-week high of $246.34.
